Barbara B. Hill Acquires 3,705 Shares of Integra Lifesciences Holdings Corp (IART) Stock

Share on StockTwits

Integra Lifesciences Holdings Corp (NASDAQ:IART) Director Barbara B. Hill purchased 3,705 shares of the company’s stock in a transaction that occurred on Monday, November 5th. The shares were purchased at an average price of $53.90 per share, for a total transaction of $199,699.50. Following the transaction, the director now owns 63,381 shares of the company’s stock, valued at approximately $3,416,235.90. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

NASDAQ IART opened at $55.49 on Wednesday. The company has a quick ratio of 2.08, a current ratio of 3.20 and a debt-to-equity ratio of 1.04. Integra Lifesciences Holdings Corp has a 52 week low of $45.96 and a 52 week high of $67.50. The company has a market cap of $4.57 billion, a price-to-earnings ratio of 28.60, a PEG ratio of 1.69 and a beta of 0.76.

Integra Lifesciences (NASDAQ:IART) last posted its quarterly earnings results on Wednesday, October 31st. The life sciences company reported $0.59 EPS for the quarter, hitting the consensus estimate of $0.59. The company had revenue of $365.85 million during the quarter, compared to analysts’ expectations of $367.89 million. Integra Lifesciences had a net margin of 5.49% and a return on equity of 16.99%. The firm’s revenue was up 31.2% on a year-over-year basis. During the same quarter in the previous year, the business posted $0.45 EPS. As a group, research analysts expect that Integra Lifesciences Holdings Corp will post 2.39 EPS for the current fiscal year.

Several equities analysts have issued reports on IART shares. BidaskClub raised shares of Integra Lifesciences from a “hold” rating to a “buy” rating in a report on Thursday, August 2nd. Bank of America downgraded shares of Integra Lifesciences from a “neutral” rating to an “underperform” rating in a research note on Tuesday, August 7th. They noted that the move was a valuation call. BTIG Research upgraded shares of Integra Lifesciences from a “neutral” rating to a “buy” rating and set a $69.00 price target for the company in a research report on Thursday, July 26th. Wells Fargo & Co dropped their price objective on shares of Integra Lifesciences from $61.00 to $55.00 and set a “market perform” rating for the company in a report on Thursday, November 1st. Finally, Cantor Fitzgerald dropped their price objective on shares of Integra Lifesciences from $59.00 to $54.00 and set a “neutral” rating for the company in a report on Thursday, November 1st. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus target price of $61.00.

Several large investors have recently modified their holdings of the company. Commonwealth Equity Services LLC lifted its position in shares of Integra Lifesciences by 8.8% during the 3rd quarter. Commonwealth Equity Services LLC now owns 11,913 shares of the life sciences company’s stock worth $784,000 after buying an additional 965 shares during the last quarter. First National Bank of Omaha lifted its position in shares of Integra Lifesciences by 2.8% during the 3rd quarter. First National Bank of Omaha now owns 39,980 shares of the life sciences company’s stock worth $2,633,000 after buying an additional 1,076 shares during the last quarter. Arizona State Retirement System lifted its position in shares of Integra Lifesciences by 2.4% during the 3rd quarter. Arizona State Retirement System now owns 50,172 shares of the life sciences company’s stock worth $3,305,000 after buying an additional 1,196 shares during the last quarter. LPL Financial LLC lifted its position in shares of Integra Lifesciences by 28.6% during the 1st quarter. LPL Financial LLC now owns 6,840 shares of the life sciences company’s stock worth $376,000 after buying an additional 1,523 shares during the last quarter. Finally, State of Alaska Department of Revenue lifted its position in shares of Integra Lifesciences by 23.1% during the 3rd quarter. State of Alaska Department of Revenue now owns 8,381 shares of the life sciences company’s stock worth $551,000 after buying an additional 1,571 shares during the last quarter. Institutional investors and hedge funds own 84.82% of the company’s stock.

WARNING: “Barbara B. Hill Acquires 3,705 Shares of Integra Lifesciences Holdings Corp (IART) Stock” was originally published by Week Herald and is owned by of Week Herald. If you are viewing this article on another domain, it was illegally copied and republished in violation of U.S. and international trademark and copyright law. The legal version of this article can be viewed at https://weekherald.com/2018/11/07/barbara-b-hill-acquires-3705-shares-of-integra-lifesciences-holdings-corp-iart-stock.html.

About Integra Lifesciences

Integra LifeSciences Holdings Corporation develops, manufactures, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery. The company operates in two segments, Codman Specialty Surgical, and Orthopedics and Tissue Technologies.

Featured Story: What is Compound Interest?

Insider Buying and Selling by Quarter for Integra Lifesciences (NASDAQ:IART)

Receive News & Ratings for Integra Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integra Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply